Visualizing solvent mediated phase transformation behavior of carbamazepine polymorphs by principal component analysis

AAPS PharmSciTech

Volumn 9, Issue 2, 2008, Pages 390-394

  Tian, Fang ^a   Rades, Thomas ^a   Sandler, Niklas ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Carbamazepine; Dihydrate; Principal component analysis

Indexed keywords

CARBAMAZEPINE; ANTICONVULSIVE AGENT; SOLVENT;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL REACTION KINETICS; DISPERSION; DRUG FORMULATION; DRUG RELEASE; DRUG STRUCTURE; DRUG TRANSFORMATION; INFRARED SPECTROSCOPY; PRINCIPAL COMPONENT ANALYSIS; RAMAN SPECTROMETRY; CHEMISTRY; COMPARATIVE STUDY; COMPUTER GRAPHICS; FOURIER ANALYSIS; METHODOLOGY; PHARMACEUTICS; PHASE TRANSITION; REGRESSION ANALYSIS; STATISTICAL MODEL;

ANTICONVULSANTS; CARBAMAZEPINE; COMPUTER GRAPHICS; FOURIER ANALYSIS; LEAST-SQUARES ANALYSIS; MODELS, STATISTICAL; PHASE TRANSITION; PRINCIPAL COMPONENT ANALYSIS; SOLVENTS; SPECTRUM ANALYSIS, RAMAN; TECHNOLOGY, PHARMACEUTICAL;

EID: 51449085329     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9049-5     Document Type: Article

References (25)

1. A. C. Jørgensen, J. Rantanen, M. Karjalainen, L. Khriachtechev, E. Rasanen, and J. Yliruusi. Hydrate formation during wet granulation studies by spectroscopic methods and multivariate analysis. Pharma. Res. 19: 1285-1291 (2002).
2. F. Tian, F. Zhang, N. Sandler, et al. Influence of sample characteristics on quantification of carbamazepine hydrate formation by X-ray powder diffraction and Raman spectroscopy. Eur. J. Pharm. Biopharm. 66: 466-474 (2007).
3. F. Tian, N. Sandler, J. Aaltonen, et al. Influence of polymorphic form, morphology and excipient interactions on the dissolution of carbamazepine compacts. J. Pharm. Sci. 96: 584-594 (2006).
4. J. Aaltonen, P. Heinänen, L. Peltonen, et al. In-situ measurement of solvent mediated phase transformations during dissolution testing. J. Pharm. Sci. 95: 2730-2737 (2006).
5. M. T. Islam, N. Rodriguez-Hornedo, S. Ciotti, and C. Ackermann. The potential of Raman spectroscopy as a process analytical technique during formulations of topical gels and emulsions. Pharm. Res. 21: 1844-1851 (2004).
6. Process Analytical Technology (PAT) initiative. The Food and Drug Administration (FDA) Website. Available at: http://www.fda.gov/cder/OPS/ PAT.htm. Accessed December 17, 2003.
7. FDA, Guidance for Industry. PAT - a framework for innovative pharmaceutical manufacturing and quality assurance, U.S. Food and Drug Administration (FDA), Rockville, MD, USA. 2004:21.
8. J. Shlens. A tutorial on principal component analysis. Available at: http://www.cs.cmu.edu/~elaw/papers/pca.pdf. Accessed December 10, 2005.
9. R. Hartley, J. Aleksandrowicz, P. C. Ng, B. Mclain, C. J. Bowmer, and W. I. Forsythe. Breakthrough seizures with generic carbamazepine: A consequence of poorer bioavailability. Br. J. Clin. Pract. 44: 270-273 (1990).
10. Anon. Moisture hardens carbamazepine tablets, FDA finds. Am. J. Hosp. Pharm. 47: 958 (1990).
11. O. Shaheen, H. Mouti, M. Karmi, M. Dadala, and S. Othman. Comparative bioavailability of two brands of carbamazepine. Curr. Ther. Res. 45: 517-524 (1989).
12. C. Lefebvre, A. M. Guyot-Hermann, M. Draguet-Brughmans, and R. Bouche. Polymorphic transitions of carbamazepine during grinding and compression. Drug Dev. Ind. Pharm. 12: 1913-1927 (1986).
13. F. U. Krahn, and J. B. Mielck. Relations between several polymorphic forms and the dihydrate of carbamazepine. Pharm. Acta. Helv. 62: 247-254 (1987).
14. A. L. Grzesiak, M. D. Lang, K. Kim, and A. J. Matzger. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J. Pharm. Sci. 92: 2260-2271 (2003).
15. F. Tian, J. A. Zeitler, C. J. Strachan, D. Saville, C. K. Gordon, and T. Rades. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. J. Pharm. Biomed. Anal 40: 271-280 (2006).
16. K. Y. Yeung, and W. L. Ruzzo. Principal component analysis for clustering gene expression data. Bioinformatics 17: 763-74 (2001).
17. I. S. Lindsay. A Tutorial on PCA. Maintained by Cornell University, USA. Available at: http://www.ucl.ac.uk/oncology/MicroCore/HTML_resource/ PCA_1.htm. Accessed February 26, 2002.
18. K. R. Beebe, R. J. Pell, and M. B. Seasholtz, eds. Chemometrics: A Practical Guide. John Wiley & Sons, Inc. A Wiley-Interscience Publication, 1998, pp. 56-182.
19. H. Martens, and T. M. Naes. Multivariate Calibration, Chapter 5, Wiley, New York, USA, 1989.
20. B. M. Wise, N. B. Gallagher, and R. Bro. PLS_Toolbox Version 3.5 (for use with MATLAB), Eigenvector Research, Inc, Manson, WA 98831, 2004.
21. L. E. O'Brien, P. Timmins, A. C. William, and P. York. Use of in situ FT-Raman spectroscopy to study the kinetics of the transformation of carbamazepine polymorphs. J. Pharm. Biomed. Anal. 36: 335-340 (2004).
22. T. Naelig;s, T. Isaksson, T. Fearn, and T. Davies, eds. A User-Friendly Guide to Multivariate Calibration and Classification. Chichester: NIR Publications, 2002, pp. 39-46.
23. F. Tian, N. Sandler, K. C. Gordon, et al. Visualizing the conversion of carbamazepine in aqueous suspension with and without the presence of excipients: A single crystal study using SEM and Raman microscopy. Eur. J. Pharm. Biopharm. 64: 326-335 (2006).
24. E. Laine, V. Tuominen, P. Iivessalo, and P. Kahela. Formation of dihydrate from carbamazepine anhydrate in aqueous conditions. Int. J. Pharm. 20: 307-314 (1984).
25. J. T. Wang, G. K. Shiu, O. C. Ting, C. T. Viswanathan, and J. P. Skelly. Effects of humidity and temperature on in-vitro dissolution of carbamazepine tablets. J. Pharm. Sci. 82: 1002-1005 (1993).